PRINCETON, N.J., April 14, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030.
Help employers find you! Check out all the jobs and post your resume.
